摘要
[目的]研究人类组织激肽释放酶(kallikrein,KLK)6蛋白在卵巢上皮性癌组织及腹膜后淋巴结中的表达,探讨其在卵巢上皮性癌中的临床意义。[方法]回顾性分析卵巢肿瘤患者的临床病理资料,采用免疫组化检测72例卵巢癌、16例卵巢交界性肿瘤、20例良性卵巢上皮性肿瘤组织KLK6蛋白的表达;并采用配对设计研究KLK6蛋白在卵巢癌患者腹膜后淋巴结中的表达,探讨KLK6在卵巢上皮性癌发生、发展中的作用。[结果]KLK6在卵巢癌及交界性卵巢肿瘤中的阳性表达分别为52.8%(38/72)、25.0%(4/16),均显著强于良性上皮性卵巢肿瘤15.0%(3/20)(P<0.05)。KLK6阳性表达与卵巢癌的临床分期、组织学分级及淋巴结转移有关(P<0.05),与组织学类型无相关性(P>0.05);KLK6在卵巢癌原发灶与腹膜后转移淋巴结组织中的表达呈正相关(r=8.91,P=0.003);KLK6阳性与阴性患者的平均生存时间分别为25.9个月和49.2个月(P<0.05)。[结论]KLK6高表达可能在卵巢上皮性癌的发生发展中起潜在作用,KLK6可能与卵巢上皮性癌的浸润、转移有关,KLK6是卵巢癌的不良预后因素之一。
[Purposel To investigate the expression of KLK6 in epithelial ovarian cancer and retroperitoneal lymph nodes, and explore its clinical significance. [ Methods ] Retrospective analysis of the clinical and pathological data of patients with ovarian tumor, immunohistoehemistry was used to detect the ex- pression of KLK6 in 72 cases of ovarian cancer, 16 cases of borderline ovarian tumor, 20 cases of benign epithelial ovarian tumor tissue. The clinicopathological data among three groups were compared. The difference of KLK6 between primary ovarian cancer tissue and retroperitoneal lymph nodes was analyzed by matched pair design. The role of KLK6 in pathogenesis and progress of ovarian cancer were discussed. [Results] Positive rate of KLK6 expression in epithelial ovarian cancers and borderline ovarian tumor were 52.8 %（38/72）, 25.0 %（4/16） respectively, which was significantly higher than that in benign epithelial ovarian tumors 15.0%（3/20）（P〈0.05）. Over-expression of KLK6 closely correlated to surgical stage, histological grade and lymphatic metastasis in ovarian cancer （P〈0.05）, but did not correlate to histological type （P〉0.05）. Positive correlation of KLK6 expression was found between primary ovarian cancer and metastatic lymph node （r=8.91,P=0.003）. Survival between positive and negative group of KLK6 were 25.9 and 49.2 months respectively （P〈0.05）. [Conclusion]The high ex- pression of KLK6 may play potential role in epithelial ovarian cancer occurrence and progress, inva- sion, and metastasis. KLK6 is one of poor prognostic factors in ovarian cancer.
出处
《肿瘤学杂志》
CAS
2009年第3期192-195,共4页
Journal of Chinese Oncology
基金
温州市科技局基金(Y20070023)
